



- (51) **International Patent Classification:**
A61K 31/404 (2006.01) *A61P 35/00* (2006.01)
C07D 413/14 (2006.01)
- (21) **International Application Number:**
PCT/US2012/032553
- (22) **International Filing Date:**
6 April 2012 (06.04.2012)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
61/473,724 8 April 2011 (08.04.2011) US
- (71) **Applicant (for all designated States except US):** **BETA PHARMA, INC.** [US/US]; 31 Business Park Drive, Branford, CT 06405 (US).
- (72) **Inventors; and**
- (71) **Applicants :** **ZHANG, Don** [US/US]; c/o Beta Pharma, Inc., 31 Business Park Drive, Branford, CT 06405 (US).
XIE, Guojian [US/US]; c/o Beta Pharma, Inc., 31 Business Park Drive, Branford, CT 06405 (US).
- (74) **Agent:** **LIU, Lance**; 4 Colonial Court, Middlebury, CT 06762 (US).
- (81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

(54) **Title:** NEW INDOLINONE PROTEIN KINASE INHIBITORS

(57) **Abstract:** The present invention relates to new indolinone compounds and their pharmaceutically acceptable salts and prodrugs for treating and preventing VEGFR related cellular disorders such as cancer.

